Research programme: synthetic biology therapeutics - Ginkgo/Synlogic
Alternative Names: Synthetic Biotic™ - Synlogic/GinkgoLatest Information Update: 28 Feb 2024
At a glance
- Originator Ginkgo Bioworks; Synlogic
- Class Hepatoprotectants; Neuroprotectants; Probiotics
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Hyperoxaluria; Liver disorders; Neurological disorders
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Hyperoxaluria in USA (PO)
- 28 Jan 2022 No recent reports of development identified for research development in Liver-disorders in USA (PO)
- 28 Jan 2022 No recent reports of development identified for research development in Neurological-disorders in USA (PO)
Development Overview
Introduction
Synlogic, in collaboration with Ginkgo Bioworks, is developing a discovery engine of living drugs for the treatment of liver, neurological disorders and secondary hyperoxaluria. The companies intend to combine Ginkgo’s automated foundry and expertise in high-throughput organism screening and design, with Synlogic’s insights and expertise in discovery, translational and clinical development of Synthetic Biotic medicines. Synlogic’s synthetic biology and microbiome technology re-engineers naturally occurring micro-organisms with genetic circuits, that transform these micro-organisms into programmable symbiotic living therapeutics, that exhibit exquisite genetic control in response to pathophysiological signals. Early research for liver disorder and neurological disorder is underway in the US. Preclinical development is underway for the treatment of secondary hyperoxaluria in the US.
Synlogic and Ginkgo will jointly seek strategic partners for portfolio expansion, clinical development, and commercialisation in neurological and liver diseases.
As at January 2022, no recent reports of development had been identified for research development in Liver-disorders in USA (PO), research development in Neurological-disorders in USA (PO).
As at February 2024, no recent reports of development had been identified for preclinical development in Hyperoxaluria in USA (PO).
Company Agreements
In August 2022, Synlogic announced clinical development of SYNB 2081 for the treatment of gout developed in partnership with Ginkgo Bioworks. SYNB 2081 is the second product to advance to clinical development through a research collaboration between Synlogic and Ginkgo. In June 2019, Synlogic and Ginkgo Bioworks announced a platform collaboration to accelerate expansion and development of Synlogic’s pipeline of Synthetic Bioticmedicines using Ginkgo’s cell programming platform. The agreement provides an $US80.0 million equity investment at a premium in Synlogic by Ginkgo and entry into a long-term strategic platform collaboration. Synlogic also paid $US30.0 million to Ginkgo for synthetic biology services to be provided over an initial period of five years which can be extended. In December 2017, Synlogic and Ginkgo had entered into a collaboration to discover new living medicines to treat neurological and liver disorders. The agreement will combine Synlogic’s insights and expertise in discovery, translational and clinical development of Synthetic Biotic medicines, with Ginkgo’s automated foundry and expertise in high-throughput organism screening and design. [1] [2]
Key Development Milestones
In January 2020, Synlogic reported that optimised oxalate-consuming strains has been transferred from Ginkgo Bioworks for the development in secondary hyperoxaluria, resulting due to excessive ingestion or absorption of oxalate from gastrointestinal tract. In preclinical studies, prototype strains has demonstrates oxalate lowering effect [3] [4] .
Drug Properties & Chemical Synopsis
- Route of administration PO
- Formulation unspecified
- Class Hepatoprotectants, Neuroprotectants, Probiotics
- Target Bacteria; Gastrointestinal microbiome
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
-
WHO ATC code
A05B-A (Liver therapy)
A16A (Other Alimentary Tract and Metabolism Products)
N07 (Other Nervous System Drugs)
-
EPhMRA code
A16A (Other Alimentary Tract and Metabolism Products)
A5B (Hepatic Protectors, Lipotropics)
N1 (Anaesthetics)
N7 (Other CNS Drugs)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| Hyperoxaluria | - | - | No development reported (Preclinical) | USA | PO / unspecified | Ginkgo Bioworks, Synlogic | 28 Feb 2024 |
| Liver disorders | - | - | No development reported (Research) | USA | PO / unspecified | Ginkgo Bioworks, Synlogic | 28 Jan 2022 |
| Neurological disorders | - | - | No development reported (Research) | USA | PO / unspecified | Ginkgo Bioworks, Synlogic | 28 Jan 2022 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| Ginkgo Bioworks | Originator | USA |
| Synlogic | Originator | USA |
| Ginkgo Bioworks | Owner | USA |
| Synlogic | Owner | USA |
Licensing Availability
| Licensing Organisation | Available Indication | Available Phase | Region | Date |
|---|---|---|---|---|
| Synlogic | - | Clinical Phase Unknown | - | 08 Dec 2017 |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 28 Feb 2024 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Hyperoxaluria in USA (PO) Updated 28 Feb 2024 |
| 28 Jan 2022 | Phase Change - No development reported | No recent reports of development identified for research development in Liver-disorders in USA (PO) Updated 28 Jan 2022 |
| 28 Jan 2022 | Phase Change - No development reported | No recent reports of development identified for research development in Neurological-disorders in USA (PO) Updated 28 Jan 2022 |
| 09 Jan 2020 | Phase Change - Preclinical | Preclinical trials in Hyperoxaluria in USA (PO) before January 2020 [3] Updated 16 Jan 2020 |
| 11 Dec 2017 | Licensing Status | Synlogic and Ginkgo Bioworks agree to develop synthetic biology therapeutics for Neurological and Liver disorders in USA [1] Updated 14 Dec 2017 |
| 11 Dec 2017 | Phase Change | Early research in Liver disorders in USA (PO) [1] Updated 14 Dec 2017 |
| 11 Dec 2017 | Phase Change | Early research in Neurological disorders in USA (PO) [1] Updated 14 Dec 2017 |
| 08 Dec 2017 | Licensing Status | Research programme: synthetic biology therapeutics - Ginkgo/Synlogic is available for licensing as of 08 Dec 2017. https://www.synlogictx.com/ Updated 04 Jan 2018 |
References
-
Synlogic and Ginkgo Bioworks Announce Collaboration as First Step Toward Building an Unprecedented Discovery Engine for Novel Living Medicines in Neurological and Liver Disorders.
Media Release -
Synlogic and Ginkgo Bioworks Establish Transformational Platform Collaboration for the Accelerated Development of Novel Synthetic Biotic(Tm) Medicines.
Media Release -
Synlogic Outlines Upcoming Milestones for Clinical Programs and Unveils New Preclinical Pipeline Programs.
Media Release -
Synlogic corpoprate presentation - January 2020. Internet-Doc 2020;.
Available from: URL: https://investor.synlogictx.com/static-files/756afa06-34b6-4e40-b051-8c665a1cc711
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG